Newsome P, et al. - Via analyzing data from a 104-week cardiovascular outcomes trial in type 2 diabetes (semaglutide 0.5 or 1.0 mg/week) and a 52-week weight management trial (semaglutide 0.05-0.4 mg/day), researchers assessed the impact of the glucagon-like peptide-1 analogue, semaglutide, on alanine aminotransferase (ALT) and high-sensitivity C-reactive protein (hsCRP) in subjects at risk of non-alcoholic fatty liver disease (NAFLD). After adjustment for weight change, treatment ratios for changes in ALT and hsCRP were not statistically significant. In clinical trials in subjects with obesity and/or type 2 diabetes, semaglutide significantly decreased ALT and hsCRP. At the higher doses of semaglutide used, these reductions were the greatest and were associated with the degree of weight loss.